Logo image of ADAG

ADAGENE INC-ADR (ADAG) Stock Fundamental Analysis

USA - NASDAQ:ADAG - US0053291078 - ADR

2.015 USD
+0.03 (+1.26%)
Last: 10/1/2025, 11:44:50 AM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ADAG. ADAG was compared to 536 industry peers in the Biotechnology industry. ADAG has a bad profitability rating. Also its financial health evaluation is rather negative. ADAG is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ADAG has reported negative net income.
ADAG had a negative operating cash flow in the past year.
ADAG had negative earnings in each of the past 5 years.
ADAG had a negative operating cash flow in each of the past 5 years.
ADAG Yearly Net Income VS EBIT VS OCF VS FCFADAG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

ADAG's Return On Assets of -44.94% is in line compared to the rest of the industry. ADAG outperforms 54.66% of its industry peers.
ADAG has a Return On Equity (-78.84%) which is in line with its industry peers.
Industry RankSector Rank
ROA -44.94%
ROE -78.84%
ROIC N/A
ROA(3y)-35.43%
ROA(5y)-39.1%
ROE(3y)-63.08%
ROE(5y)-60.3%
ROIC(3y)N/A
ROIC(5y)N/A
ADAG Yearly ROA, ROE, ROICADAG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

ADAG does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ADAG Yearly Profit, Operating, Gross MarginsADAG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -10K -20K -30K

More info and screens

2

2. Health

2.1 Basic Checks

ADAG does not have a ROIC to compare to the WACC, probably because it is not profitable.
ADAG has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ADAG has more shares outstanding
Compared to 1 year ago, ADAG has a worse debt to assets ratio.
ADAG Yearly Shares OutstandingADAG Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
ADAG Yearly Total Debt VS Total AssetsADAG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -5.85, we must say that ADAG is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of ADAG (-5.85) is worse than 63.25% of its industry peers.
A Debt/Equity ratio of 0.06 indicates that ADAG is not too dependend on debt financing.
ADAG's Debt to Equity ratio of 0.06 is on the low side compared to the rest of the industry. ADAG is outperformed by 61.38% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Altman-Z -5.85
ROIC/WACCN/A
WACC8.59%
ADAG Yearly LT Debt VS Equity VS FCFADAG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

A Current Ratio of 2.29 indicates that ADAG has no problem at all paying its short term obligations.
ADAG has a worse Current ratio (2.29) than 71.08% of its industry peers.
ADAG has a Quick Ratio of 2.29. This indicates that ADAG is financially healthy and has no problem in meeting its short term obligations.
ADAG has a Quick ratio of 2.29. This is in the lower half of the industry: ADAG underperforms 69.03% of its industry peers.
Industry RankSector Rank
Current Ratio 2.29
Quick Ratio 2.29
ADAG Yearly Current Assets VS Current LiabilitesADAG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 10.98% over the past year.
The Revenue for ADAG has decreased by -87.35% in the past year. This is quite bad
Measured over the past years, ADAG shows a very negative growth in Revenue. The Revenue has been decreasing by -26.47% on average per year.
EPS 1Y (TTM)10.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.71%
Revenue 1Y (TTM)-87.35%
Revenue growth 3Y-78.36%
Revenue growth 5Y-26.47%
Sales Q2Q%N/A

3.2 Future

ADAG is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 4.90% yearly.
The Revenue is expected to grow by 56.32% on average over the next years. This is a very strong growth
EPS Next Y13.69%
EPS Next 2Y-5.37%
EPS Next 3Y5.02%
EPS Next 5Y4.9%
Revenue Next Year-17.84%
Revenue Next 2Y2.67%
Revenue Next 3Y-9.87%
Revenue Next 5Y56.32%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ADAG Yearly Revenue VS EstimatesADAG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M
ADAG Yearly EPS VS EstimatesADAG Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ADAG. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ADAG. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ADAG Price Earnings VS Forward Price EarningsADAG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ADAG Per share dataADAG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-5.37%
EPS Next 3Y5.02%

More info and screens

0

5. Dividend

5.1 Amount

ADAG does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADAGENE INC-ADR

NASDAQ:ADAG (10/1/2025, 11:44:50 AM)

2.015

+0.03 (+1.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12 2025-08-12/amc
Earnings (Next)03-23 2026-03-23/amc
Inst Owners23.51%
Inst Owner Change-5.54%
Ins Owners2.77%
Ins Owner ChangeN/A
Market Cap94.93M
Analysts80
Price Target9.84 (388.34%)
Short Float %0.13%
Short Ratio0.49
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-4.56%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)15.3%
EPS NY rev (3m)18.15%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-24.04%
Revenue NY rev (3m)14%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 919.82
P/FCF N/A
P/OCF N/A
P/B 2.5
P/tB 2.5
EV/EBITDA N/A
EPS(TTM)-0.64
EYN/A
EPS(NY)-0.74
Fwd EYN/A
FCF(TTM)-0.58
FCFYN/A
OCF(TTM)-0.58
OCFYN/A
SpS0
BVpS0.8
TBVpS0.8
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -44.94%
ROE -78.84%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-35.43%
ROA(5y)-39.1%
ROE(3y)-63.08%
ROE(5y)-60.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.25%
Cap/Sales 22.77%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.29
Quick Ratio 2.29
Altman-Z -5.85
F-Score2
WACC8.59%
ROIC/WACCN/A
Cap/Depr(3y)24.44%
Cap/Depr(5y)80.95%
Cap/Sales(3y)13.48%
Cap/Sales(5y)39.88%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)10.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.71%
EPS Next Y13.69%
EPS Next 2Y-5.37%
EPS Next 3Y5.02%
EPS Next 5Y4.9%
Revenue 1Y (TTM)-87.35%
Revenue growth 3Y-78.36%
Revenue growth 5Y-26.47%
Sales Q2Q%N/A
Revenue Next Year-17.84%
Revenue Next 2Y2.67%
Revenue Next 3Y-9.87%
Revenue Next 5Y56.32%
EBIT growth 1Y9.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year17.1%
EBIT Next 3Y-15.12%
EBIT Next 5YN/A
FCF growth 1Y-4.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-4.38%
OCF growth 3YN/A
OCF growth 5YN/A